Small Cell Lung Cancer: A New Era Is Beginning?
- PMID: 34071158
- PMCID: PMC8197965
- DOI: 10.3390/cancers13112646
Small Cell Lung Cancer: A New Era Is Beginning?
Abstract
Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers and it is the most aggressive one [...].
Conflict of interest statement
The authors declare the following conflicts of interest: A.M. received honoraria from Roche, AstraZeneca, Boehringer, MSD, BMS, Pfizer, Takeda, Lilly, Novartis. C.R. received honoraria as a speaker: MSD, Roche, Astra Zeneca, Advisory board: Inivata, ArcherDx, MD Serono, Novartis, Boston Pharmaceuticals, BMS, Research Grant: Lung Cancer Research Foundation-Pfizer Grant 2019 American Cancer Society Research Collaboration non remunerated: Guardant Health.
References
-
- Lazzari C., Mirabile A., Bulotta A., Viganò M.G., Ogliari F.R., Ippati S., Dell Oca I., Santarpia M., Lorusso V., Reck M., et al. History of extensive disease small cell lung cancer treatment: Time to raise the bar? A review of the literature. Cancers. 2021;13:998. doi: 10.3390/cancers13050998. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources